Scienmag
OCTOBER 23, 2020
Oncotarget recently published a novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion Credit: Correspondence to – Dario Neri – dario.neri@pharma.ethz.ch
XTalks
DECEMBER 12, 2023
The team includes outstanding scientists and researchers around the world who look to push the boundaries of what’s possible to discover the next breakthroughs. Our pipeline, for example, includes a new class of recombinant antibodies. The science is brilliant.
Drug Discovery World
NOVEMBER 9, 2023
The two luncheon presentations include: Maurice Brozzo, Global Antibody Specialist, Charles River, on: ‘The antibody discovery journey: from next-generation libraries to efficacy and safety’. Jorge Dias, PhD, Principal Scientist, Alchemab Therapeutics, on: ‘A patient-first approach to discover first-in-class antibody therapeutics’.
Expert insights. Personalized for you.
53 
Let's personalize your content